Mycophenolate Hexal (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolate Hexal, is an antimetabolite presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis and vasculitis. GNH USA supplies Mycophenolate Hexal as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mycophenolate Hexal is used to suppress immune activity in transplant and autoimmune disease settings. - Organ transplant rejection prevention: reduces the risk of acute and chronic graft rejection by inhibiting lymphocyte proliferation. - Lupus nephritis: helps control renal inflammation and preserve kidney function in systemic lupus erythematosus. - Vasculitis: contributes to disease control by limiting immune‑mediated vessel inflammation.

Mycophenolate Hexal may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain. - Hematologic changes: anemia, leukopenia, or thrombocytopenia. - Infections: increased susceptibility to bacterial, viral, or fungal infections. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain disease. - Malignancy: increased risk of lymphoproliferative disorders or skin cancers. - Pregnancy complications: fetal toxicity and miscarriage.

Before prescribing Mycophenolate Hexal, clinicians should consider several safety precautions. - Pregnancy risk: category D, avoid use during pregnancy unless benefits outweigh risks. - Breastfeeding: contraindicated, as drug is excreted in milk. - Renal impairment: adjust dose and monitor renal function. - Hepatic impairment: use with caution and monitor liver enzymes. - Infection monitoring: screen for latent infections and monitor for new infections. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Mycophenolate Hexal can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of mycophenolic acid. - Azathioprine: additive bone marrow suppression. - Live vaccines: increased risk of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase mycophenolate levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): decrease drug exposure. - Non‑live vaccines: may have reduced efficacy, monitor immune response.